Tous Actualités
Suivre
Abonner SYGNIS AG

SYGNIS AG

EANS-News: SYGNIS Pharma AG
SYGNIS announces Data Safety Monitoring Board Recommendation for Phase II efficacy study for AX200

Heidelberg (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Research & Development
SYGNIS announces Data Safety Monitoring
Board Recommendation for Phase II efficacy study for AX200
- more than 50% of the AXIS 2-patients recruited
    - top-line data expected in the second half of 2011
Heidelberg,  22  December  2010  -  SYGNIS  Pharma  AG  (Frankfurt:  
LIOK;  ISIN DE000A1E9B74; Prime Standard),  a  clinical  stage  
biotech  company  developing innovative CNS treatments, today 
announced  that  the  independent  Data  Safety Monitoring Board 
(DSMB) for the  Phase  II  efficacy  study  of  AX200  for  the 
treatment of acute ischemic Stroke  (AXIS  2)  has  recommended  the 
unmodified continuation of the trial. AX200 is SYGNIS´ most advanced 
drug candidate.
Based on the data of 50% of  the  AXIS  2-patients  the  DSMB  held  
its  second interim  review.  As  the  available   study-results   
have   shown   that   the administration of AX200 is safe and  well  
tolerated  in  the  patients  treated within the study, the DSMB´s 
recommendation is to  continue  the  study  without any modification 
or restriction.
The role of the DSMB is to monitor, periodically, the  data  emerging
from  the study to determine whether there are safety issues arising 
that  would  warrant modification of the protocol or early 
termination of  the  study.  The  DSMB  is independent of SYGNIS and 
any party related to SYGNIS.
AXIS 2 is a randomised double-blind study involving a  total  of  328
patients; half of the patients are treated with AX200, while the 
other  half  is  given  a placebo. The study is designed to 
demonstrate the  efficacy  of  AX200  for  the treatment of patients 
with acute ischemic stroke compared with a placebo  group. Patients 
are enrolled in the study up to nine hours after the  occurrence  of 
a stroke, with the study  medication  administered  as  a  continuous
intravenous (i.v.) infusion for a period of three days. The trial was
initiated in May  2009 and involves more than 70 sites  in  eight  
European  countries.  Based  on  the latest preclinical data the 
study protocol was modified in spring 2010  to  also allow 
recruitment of patients previously treated with rt-PA.
Dr Frank  Rathgeb,  Chief  Medical  Officer  of  SYGNIS,  said:  
"This  news  is certainly confirming our high expectations regarding 
the  safety  of  AX200  and the quality of the AXIS 2 study. There is
good reason to continue the  study  as planned and to confirm our 
planning to report the top-line data  in  the  second half of 2011."
About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,  
is  a  specialty  pharmaceutical company listed on the Prime Standard
of the German stock exchange.  The  Company is focused on the 
research and  development  of  innovative  therapies  for  the 
treatment of disorders of the Central Nervous System. SYGNIS´ core 
projects  are currently Acute Stroke for which SYGNIS´ lead clinical 
programme  is  AX200  as well as the preclinical KIBRA-project for 
the treatment of  different  forms  of dementia. All these disorders 
are  characterized  by  the  fact  that,  as  the disease progresses,
nerve cells are damaged and die.  Although  there  is  great medical 
demand, there are currently no  or  only  inadequate  treatment  
options available. SYGNIS´ strategy for growth includes the 
development of new  products from its own research and through 
in-licensing and acquisitions.
For further information please contact:
SYGNIS Pharma AG:
Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812 
franz-werner.haas@sygnis.de
Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187
### Disclaimer Some statements included in this  press  release,  
relating  neither  to  proven financial results nor other  historical
data,  should  be  viewed  as  forward- looking, i.e. not definite. 
Such statements are  mainly  predictions  of  future results, trends,
plans or goals. These statements should not  be  considered  to be 
total guarantees since given their very nature they are subject to 
known  and unknown risks and imponderability and can be affected  by 
other  factors  as  a consequence of which the actual results, plans 
and goals  of  SYGNIS  Pharma  AG may deviate greatly from the  
established  conclusions  or  implied  predictions contained in such 
statements. SYGNIS does not undertake to  publicly  update  or revise
these statements in the light of new information  or  future  results
or for any other reason.  ###
end of announcement                               euro adhoc

Further inquiry note:

Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE000A1E9B74
WKN: A1E9B7
Index: CDAX, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade

Plus de actualités: SYGNIS AG
Plus de actualités: SYGNIS AG
  • 11.11.2010 – 08:51

    EANS-News: SYGNIS announces six month results of fiscal year 2010/2011

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. 6-month report Heidelberg (euro adhoc) - SYGNIS announces six month results of fiscal year 2010/2011 Heidelberg, 11 November 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today published its ...

  • 29.10.2010 – 09:42

    EANS-Adhoc: SYGNIS Pharma AG announces strategic restructuring

    ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information 29.10.2010 Ad-hoc SYGNIS Pharma AG announces strategic restructuring Heidelberg, 29 October 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) announced today a ...